Rex Hermansen, MD

Apixaban noninferior to low-molecular-weight heparin in cancer-associated VTE

Publish date: December 6, 2021

Is oral apixaban as safe and effective as subcutaneous dalteparin in treating venous thromboembolism (VTE) in patients with underlying cancer?